Shuichi Nagashima
Overview
Explore the profile of Shuichi Nagashima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamada H, Morimoto J, Funazaki S, Tonezawa S, Takahashi A, Yoshida M, et al.
J Clin Med Res
. 2023 Oct;
15(8-9):406-414.
PMID: 37822852
Background: The aim of the study was to provide real-world data on the effectiveness and safety of a new fixed-ratio combination, insulin degludec/liraglutide (IDegLira) injection in Japanese patients with type...
2.
Shibuya K, Ebihara K, Takahashi M, Kurashina T, Nagashima S, Okada K, et al.
JMA J
. 2023 May;
6(2):216-219.
PMID: 37179722
Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic disorder, resulting from gene abnormalities, which causes tumors mainly in the endocrine glands. We experienced a sporadic case of MEN1...
3.
Yamada H, Yoshida M, Funazaki S, Morimoto J, Tonezawa S, Takahashi A, et al.
J Cardiovasc Dev Dis
. 2023 Apr;
10(4).
PMID: 37103055
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide...
4.
Yamada H, Yoshida M, Suzuki D, Funazaki S, Nagashima S, Masahiko K, et al.
Diabetes Ther
. 2023 Jan;
14(3):619-620.
PMID: 36627460
No abstract available.
5.
Yamada H, Yoshida M, Suzuki D, Funazaki S, Nagashima S, Masahiko K, et al.
Diabetes Ther
. 2022 Aug;
13(10):1779-1788.
PMID: 36006593
Introduction: Once-weekly (OW) glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide has been shown to have a more potent glycated hemoglobin (HbA1c)-lowering effect than other oral hypoglycemic agents and existing GLP-1RAs...
6.
Takahashi M, Yamamuro D, Wakabayashi T, Takei A, Takei S, Nagashima S, et al.
J Biol Chem
. 2022 Aug;
298(9):102322.
PMID: 35926714
During obesity, tissue macrophages increase in number and become proinflammatory, thereby contributing to metabolic dysfunction. Lipoprotein lipase (LPL), which hydrolyzes triglyceride in lipoproteins, is secreted by macrophages. However, the role...
7.
Hatano Y, Sawayama N, Miyashita H, Kurashina T, Okada K, Takahashi M, et al.
J Endocr Soc
. 2022 Jul;
6(8):bvac098.
PMID: 35822200
Context: The association between primary aldosteronism and obesity, especially its sex difference, remains unknown. Objective: To assess the association for each subtype of primary aldosteronism with obesity parameters including visceral...
8.
Shibuya K, Ebihara K, Ebihara C, Sawayama N, Isoda M, Yamamuro D, et al.
J Biol Chem
. 2022 Apr;
298(6):101936.
PMID: 35430252
Valosin-containing protein (VCP) is a member of AAA-ATPase superfamily involved in various cellular functions. To investigate the pathophysiological role of VCP in metabolic disorders, we generated knock-in mice bearing an...
9.
Funazaki S, Yoshida M, Yamada H, Kakei M, Kawakami M, Nagashima S, et al.
J Diabetes Investig
. 2021 Sep;
13(1):34-41.
PMID: 34523242
Aims/introduction: Imeglimin is a novel oral hypoglycemic agent that improves blood glucose levels through multiple mechanisms of action including the enhancement of glucose-stimulated insulin secretion (GSIS), however, the details of...
10.
Isoda M, Ebihara K, Sawayama N, Murakami A, Ebihara C, Shibuya K, et al.
Sci Rep
. 2021 Sep;
11(1):17691.
PMID: 34489483
Leptin is an adipocyte-derived hormone that regulates appetite and energy expenditure via the hypothalamus. Since the majority of obese subjects are leptin resistant, leptin sensitizers, rather than leptin itself, are...